FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3031248945> ?p ?o ?g. }

• W3031248945 endingPage "e034565" @default.
• W3031248945 startingPage "e034565" @default.
• W3031248945 abstract "Target-specific anticancer drugs are under rapid development. Little is known, however, about the risk of administering target-specific drugs to patients who have tumours with molecular alterations or other characteristics that can make the drug ineffective or even harmful. An increasing number of randomised clinical trials (RCTs) investigating target-specific anticancer drugs include subgroup analyses based on tumour characteristics. Such subgroup analyses have the potential to be more credible and influential than subgroup analyses based on traditional factors such as sex or tumour stage. In addition, they may more frequently lead to qualitative subgroup effects, that is, show benefit in one but harm in another subgroup of patients (eg, if the tumour characteristic makes the drug ineffective or even enhance tumour growth). If so, subgroup analyses based on tumour characteristics would be highly relevant for patient safety. The aim of this study is to systematically assess the frequency and characteristics of subgroup analyses based on tumour characteristics, the frequency of qualitative subgroup effects, their credibility, and the interpretations that investigators and guidelines developers report.We will perform a systematic survey of 433 RCTs testing the effect of target-specific anticancer drugs. Teams of methodologically trained investigators and oncologists will identify eligible studies, extract relevant data and assess the credibility of putative subgroup effects using a recently developed formal instrument. We will systematically assess how trial investigators interpret apparent subgroup effects based on tumour characteristics and the extent to which they influence subsequent practice guidelines. Our results will provide empirical data characterising an increasingly used type of subgroup analysis in cancer trials and its potential impact on precision medicine to predict benefit or harm.Formal ethical approval is not required for this study. We will disseminate the findings in a peer-reviewed and open-access journal publication." @default.
• W3031248945 created "2020-06-05" @default.
• W3031248945 creator A5008197383 @default.
• W3031248945 creator A5011578307 @default.
• W3031248945 creator A5017224763 @default.
• W3031248945 creator A5019888759 @default.
• W3031248945 creator A5020462726 @default.
• W3031248945 creator A5031717153 @default.
• W3031248945 creator A5075098080 @default.
• W3031248945 creator A5084978936 @default.
• W3031248945 creator A5089083291 @default.
• W3031248945 date "2020-05-01" @default.
• W3031248945 modified "2023-09-25" @default.
• W3031248945 title "Characteristics and interpretation of subgroup analyses based on tumour characteristics in randomised trials testing target-specific anticancer drugs: design of a systematic survey" @default.
• W3031248945 cites W1592228396 @default.
• W3031248945 cites W1971141955 @default.
• W3031248945 cites W1980421533 @default.
• W3031248945 cites W2035655846 @default.
• W3031248945 cites W2036246082 @default.
• W3031248945 cites W2040273058 @default.
• W3031248945 cites W2065350134 @default.
• W3031248945 cites W2085633477 @default.
• W3031248945 cites W2092961885 @default.
• W3031248945 cites W2098931866 @default.
• W3031248945 cites W2108233388 @default.
• W3031248945 cites W2108310865 @default.
• W3031248945 cites W2111404068 @default.
• W3031248945 cites W2132870547 @default.
• W3031248945 cites W2147219701 @default.
• W3031248945 cites W2148173212 @default.
• W3031248945 cites W2149974876 @default.
• W3031248945 cites W2160540948 @default.
• W3031248945 cites W2218942987 @default.
• W3031248945 cites W2341847061 @default.
• W3031248945 cites W2409498199 @default.
• W3031248945 cites W2410682816 @default.
• W3031248945 cites W2469201213 @default.
• W3031248945 cites W2527905628 @default.
• W3031248945 cites W2554898265 @default.
• W3031248945 cites W2560833249 @default.
• W3031248945 cites W2595252694 @default.
• W3031248945 cites W2891267158 @default.
• W3031248945 cites W2901826044 @default.
• W3031248945 cites W2946263550 @default.
• W3031248945 doi "https://doi.org/10.1136/bmjopen-2019-034565" @default.
• W3031248945 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7264639" @default.
• W3031248945 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32474426" @default.
• W3031248945 hasPublicationYear "2020" @default.
• W3031248945 type Work @default.
• W3031248945 sameAs 3031248945 @default.
• W3031248945 citedByCount "0" @default.
• W3031248945 crossrefType "journal-article" @default.
• W3031248945 hasAuthorship W3031248945A5008197383 @default.
• W3031248945 hasAuthorship W3031248945A5011578307 @default.
• W3031248945 hasAuthorship W3031248945A5017224763 @default.
• W3031248945 hasAuthorship W3031248945A5019888759 @default.
• W3031248945 hasAuthorship W3031248945A5020462726 @default.
• W3031248945 hasAuthorship W3031248945A5031717153 @default.
• W3031248945 hasAuthorship W3031248945A5075098080 @default.
• W3031248945 hasAuthorship W3031248945A5084978936 @default.
• W3031248945 hasAuthorship W3031248945A5089083291 @default.
• W3031248945 hasBestOaLocation W30312489451 @default.
• W3031248945 hasConcept C126322002 @default.
• W3031248945 hasConcept C143998085 @default.
• W3031248945 hasConcept C17744445 @default.
• W3031248945 hasConcept C187960798 @default.
• W3031248945 hasConcept C19527891 @default.
• W3031248945 hasConcept C199539241 @default.
• W3031248945 hasConcept C2777363581 @default.
• W3031248945 hasConcept C2779473830 @default.
• W3031248945 hasConcept C2780224610 @default.
• W3031248945 hasConcept C512399662 @default.
• W3031248945 hasConcept C535046627 @default.
• W3031248945 hasConcept C71924100 @default.
• W3031248945 hasConcept C95190672 @default.
• W3031248945 hasConceptScore W3031248945C126322002 @default.
• W3031248945 hasConceptScore W3031248945C143998085 @default.
• W3031248945 hasConceptScore W3031248945C17744445 @default.
• W3031248945 hasConceptScore W3031248945C187960798 @default.
• W3031248945 hasConceptScore W3031248945C19527891 @default.
• W3031248945 hasConceptScore W3031248945C199539241 @default.
• W3031248945 hasConceptScore W3031248945C2777363581 @default.
• W3031248945 hasConceptScore W3031248945C2779473830 @default.
• W3031248945 hasConceptScore W3031248945C2780224610 @default.
• W3031248945 hasConceptScore W3031248945C512399662 @default.
• W3031248945 hasConceptScore W3031248945C535046627 @default.
• W3031248945 hasConceptScore W3031248945C71924100 @default.
• W3031248945 hasConceptScore W3031248945C95190672 @default.
• W3031248945 hasFunder F4320320924 @default.
• W3031248945 hasIssue "5" @default.
• W3031248945 hasLocation W30312489451 @default.
• W3031248945 hasLocation W30312489452 @default.
• W3031248945 hasLocation W30312489453 @default.
• W3031248945 hasLocation W30312489454 @default.
• W3031248945 hasOpenAccess W3031248945 @default.
• W3031248945 hasPrimaryLocation W30312489451 @default.
• W3031248945 hasRelatedWork W2041803801 @default.
• W3031248945 hasRelatedWork W2114338569 @default.

• next